WuXi Biologics: Clinical trial application for Varicella Vaccine granted acceptance.

Watson Bio announced that the attenuated varicella vaccine, which was jointly developed by the company and its subsidiaries, has applied for clinical trials with the National Medical Products Administration and recently received the "Acceptance Notification". This vaccine uses the attenuated strain of varicella-zoster virus to infect human diploid cells, which are then processed by freeze-drying technology to prevent chickenpox. Varicella-zoster virus is highly contagious and can cause chickenpox and shingles. Currently, major overseas producers of varicella attenuated live vaccines include Japan's Biken Company, the United States' Merck & Co., and the United Kingdom's GlaxoSmithKline. In China, six companies have already obtained marketing approval. The acceptance of the clinical trial application for this vaccine will not have a significant impact on the company's operating performance for the current year.